Sugi Predict

Sugi Predict / Compounds / SCHEMBL1573386

SCHEMBL1573386

SCHEMBL1573386

O=C(CCBr)Nc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ MAPT P10636 2/20 0.63
▸ HTT P42858 1/20 0.63
▸ HDAC4 P56524 9/20 0.59
▸ HDAC1 Q13547 9/20 0.59
▸ HDAC7 Q8WUI4 9/20 0.59
▸ HDAC11 Q96DB2 9/20 0.59
▸ HDAC8 Q9BY41 9/20 0.59
▸ HDAC6 Q9UBN7 9/20 0.59
▸ HDAC9 Q9UKV0 9/20 0.59
▸ HDAC5 Q9UQL6 9/20 0.59
▸ HDAC3 O15379 8/20 0.59
▸ HDAC2 Q92769 8/20 0.59
▸ HDAC10 Q969S8 8/20 0.59
▸ CYP3A4 P08684 2/20 0.59
▸ NCOR1 O75376 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ BRD4 O60885 1/20 0.59
▸ NR1I2 O75469 1/20 0.59
▸ EGFR P00533 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8132454 0.88 HDAC4 (0.66) L3MBTL1MAPTHTTHDAC4HDAC1
SCHEMBL3342586 0.87 L3MBTL1 (0.80) L3MBTL1MAPTHTTHDAC4HDAC1
SCHEMBL31112364 0.86 L3MBTL1 (0.53) L3MBTL1MAPTHTTHDAC4HDAC1
SCHEMBL31203466 0.86 HDAC4 (0.69) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL19962686 0.86 POLB (0.65) MAPTHTTHDAC4HDAC1HDAC7
SCHEMBL10435604 0.85 L3MBTL1 (0.66) L3MBTL1MAPTHTTHDAC4HDAC1
SCHEMBL4837637 0.85 HDAC4 (0.72) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL14934835 0.85 HDAC4 (0.72) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL8178246 0.85 HDAC4 (0.72) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL517309 0.83 HDAC4 (0.81) HDAC4HDAC1HDAC7HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104003895-B A kind of method of cascade reaction synthesis Terphenyls compound of palladium chtalyst HEILONGJIANG UNIVERSITY (CN) 2016-02-24 — — CN claimed
CN-104119266-A Method for preparing carbazole from phenolic compound UNIV ZHEJIANG 2014-10-29 — — CN claimed
CN-104003895-A Method for synthetizing terphenyl compounds through palladium catalyzed cascade reaction UNIV HEILONGJIANG 2014-08-27 — — CN claimed
CN-118255686-A Fluorine-containing trans-phenyl cyclopropylamine derivative, and preparation method and application thereof 郑州大学 2024-06-28 — — CN disclosed
CN-111978252-A Chiral benzomorphane derivative and preparation method and pharmaceutical application thereof 复旦大学 2020-11-24 — — CN disclosed
CN-104003895-B A kind of method of cascade reaction synthesis Terphenyls compound of palladium chtalyst HEILONGJIANG UNIVERSITY (CN) 2016-02-24 — — CN disclosed
CN-104119266-A Method for preparing carbazole from phenolic compound UNIV ZHEJIANG 2014-10-29 — — CN disclosed
CN-104003895-A Method for synthetizing terphenyl compounds through palladium catalyzed cascade reaction UNIV HEILONGJIANG 2014-08-27 — — CN disclosed
US-20130165479-A1 ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF ABBVIE, INC. (US) 2013-06-27 — — US disclosed
US-8350083-B2 Antagonists of the TRPV1 receptor and uses thereof ABBVIE INC. (US) 2013-01-08 — — US disclosed
US-20120022103-A1 ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF ABBOTT LABORATORIES (US) 2012-01-26 — — US disclosed
CN-1046731-C Pyrrolo [2,3-d ] pyrimidines and their use NOVARTIS AG (CH) 1999-11-24 — — CN disclosed
CN-1164234-A Pyrrolo [2, 3-d ] pyrimidines and their use NOVARTIS AG (CH) 1997-11-05 — — CN disclosed
EP-0488861-A1 Process for the preparation of alkoxylated aromatic compounds RHONE-POULENC CHIMIE (FR) 1992-06-03 — — EP disclosed
EP-0455545-A1 Process for the preparation of mono- or polyalkoxylated aromatic compounds RHONE-POULENC CHIMIE (FR) 1991-11-06 — — EP disclosed
EP-0434517-A2 Process for the preparation of mono- or poly-alkoxylated aromatic compounds RHONE-POULENC CHIMIE (FR) 1991-06-26 — — EP disclosed
EP-0434516-A2 Process for the preparation of mono- or poly-alkoxylated aromatic compounds RHONE-POULENC CHIMIE (FR) 1991-06-26 — — EP disclosed
US-4407939-A GELATIN MODIFIED WITH SUCCINIC, PHTHALIC OR TRIMELLITIC ANHYDRIDE POSITIONED BETWEEN FUJI PHOTO FILM CO., LTD. (JP) 1983-10-04 — — US disclosed
US-4111933-A PROTECTION OF FUNCTIONAL GROUPS DURING REACTION AND THEIR SUBSEQUENT RESTORATION BAYER AKTIENGESELLSCHAFT (DE) 1978-09-05 — — US disclosed
US-4021245-A GELATION DERIVATIVE, SILICIC ACID ANHYDRIDE FUJI PHOTO FILM CO., LTD. (JA) 1977-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165479-A1 ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF TRPV1, TRPV3, TRPV2 L3MBTL1 1518/4885MAPT 2573/4885HTT 3282/4885
US-20120022103-A1 ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF TRPV1, TRPV3, TRPV2 L3MBTL1 1477/4885MAPT 2392/4885HTT 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.